Investigation on the Payment Management of Targeted Therapy and Immunotherapy for Malignant Tumors in DRG Group
- VernacularTitle:DRG组恶性肿瘤靶向、免疫治疗支付管理调查研究
- Author:
Licheng ZHANG
1
;
Ming GAO
1
;
Jiahua LENG
1
Author Information
1. 北京大学肿瘤医院暨北京市肿瘤防治研究所·恶性肿瘤发病机制及转化研究教育部重点实验室 北京 100142
- Publication Type:Journal Article
- Keywords:
DRG;
targeted therapy and immunotherapy;
payment management
- From:
Chinese Hospital Management
2025;45(2):50-52
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the cost and payment management of DRG group malignant tumor targeted therapy and immunotherapy(RG19)in medical institutions,and provide reference suggestions for further improving DRG related systems.Methods A questionnaire survey was conducted on clinical doctors and medical insurance staff from 96 comprehensive hospitals and oncology specialized hospitals in 22 DRG pilot cities in China.The questions included the hospital management of RG19 group,and special payment policies in different regions.Results A total of 148 valid questionnaires were collected.The survey results showed that 37％of hospitals in the RG19 group was in a loss state,mainly due to the use of innovative drugs and the high proportion of targeted therapy and immunotherapy combined cases.46％of respondents believed that the current payment standards for RG19 group did not fully reflect the value of doctor plan development,and the grouping rules needed to be further optimized.Factors such as line of treatment,and drug use types should be comprehensively considered.In addition,24％of hospitals RG19 group made profits due to the high proportion of clinical trial cases,but most regions did not have special policies for payment of clinical trial cases.Conclusion Medical institutions should further strengthen the management of hospital internal cost control for DRG patients,and regions should pay more attention to clinical practice in formulating DRG grouping rules and payment schemes.
